Gergana I. G.
- Country
- Bulgaria
- Department
- NA
Research Overview
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- Efficacy and Safety of Tanimilast DPI as Add-On to Triple Therapy in Chronic Obstructive Pulmonary Disease with Chronic Bronchitis
- Efficacy and Safety Evaluation of Tanimilast (CHF6001) as an Add-On to Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
Data & Insights
Has run more than one trial at 121 of 234 partner sites.
Specializations
Respiratory Medicine
This investigator specializes in the treatment of Chronic Obstructive Pulmonary Disease (COPD), with particular expertise in advanced therapeutic interventions for patients with severe respiratory conditions.
- COPD Management
- Chronic Bronchitis Treatment
- Respiratory Disease Care
Their research focuses on innovative therapeutic approaches for managing chronic respiratory conditions.
Treatment Innovation
The investigator explores advanced therapeutic combinations, including triple therapy maintenance treatments for respiratory disorders, particularly focusing on enhancing existing treatment protocols.
- Combined Therapy Approaches
- Long-term Disease Management
- Treatment Optimization
Their work encompasses the evaluation of novel therapeutic agents as additions to established treatment regimens.
Clinical Outcomes
The investigator's expertise extends to studying exacerbation management in chronic respiratory conditions, with a focus on reducing the frequency and severity of COPD episodes.
- Disease Exacerbation Control
- Long-term Efficacy Assessment
- Patient Response Monitoring
Their research emphasizes the development of therapeutic strategies for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.